Amanda Matteson, PA
Medical · Providence, RINPI 1952470007
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,225 of the $8,492 with a category attached, or 61.5%. 21 manufacturers reported payments, led by Sanofi at 50.3% of the total. Reporting peaked in 2024 at $3,987 and has fallen 92.4% since, to $304 in 2025. Among medical clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 211 payments — averaging $40.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$4K
- AstraZeneca$1K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$828
- Teva Pharmaceuticals USA, Inc.$129
- Boehringer Ingelheim$125
- plus $839 from 15 others
What the payments were for
- Consulting fees$2,32827%
- Travel & lodging$93911%
- Food & beverage$5,22562%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 24 | $4,270 |
| AstraZeneca | 47 | $1,209 |
| GSK | 54 | $1,093 |
| Regeneron Healthcare Solutions, Inc. | 32 | $828 |
| Teva Pharmaceuticals USA, Inc. | 6 | $129 |
| Boehringer Ingelheim | 5 | $125 |
| Kaleo, Inc. | 7 | $120 |
| Covis Pharma GmbH | 5 | $89 |
| AbbVie | 4 | $88 |
| Optinose US, Inc. | 4 | $88 |
| Hikma Pharmaceuticals USA | 3 | $67 |
| Aimmune Therapeutics, Inc. | 3 | $56 |
| Genentech USA, Inc. | 3 | $55 |
| Amgen(2 entities) | 3 | $52 |
| Pfizer | 2 | $45 |
| LEO Pharma Inc. | 2 | $43 |
| Novartis | 3 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Grifols USA, LLC | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| CSL Behring | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,492 in reported general payments places this provider in the 95th percentile of 77 medical providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 863 | $588,813 |
| OfevNintedanib Esylate | 20 | $258,862 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 189 | $118,080 |
| Dupixent PenDupilumab | 26 | $100,590 |
| Breo ElliptaFluticasone/Vilanterol | 159 | $67,018 |
| Spiriva RespimatTiotropium Bromide | 76 | $43,915 |
| XolairOmalizumab | 32 | $40,914 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 70 | $32,684 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 128 | $30,149 |
| SymbicortBudesonide/Formoterol Fumarate | 83 | $25,868 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $25,111 |
| Qvar RedihalerBeclomethasone Dipropionate | 58 | $16,718 |
| Arnuity ElliptaFluticasone Furoate | 67 | $15,007 |
| Advair HfaFluticasone Propion/Salmeterol | 35 | $12,044 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 367 | $11,314 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,093 | $704,3291,156 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $125 | $335,461166 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,209 | $143,948272 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $129 | $16,71858 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 77 medical providers in Rhode Island.
Other medical in Providence
- Jason XynellisProvidence$7K
- Ian KrousonProvidence$5K
- Ernest SilvaProvidence$3K
- Joseph DesrosiersProvidence$2K
- Kailey WellsProvidence$2K
- Daniel PiascikProvidence$2K
- Sonia PeckProvidence$2K
- Phathsady LouangxayProvidence$1K
- Shauna SnitkoProvidence$835
- Kenneth FurcoloProvidence$511
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.